MedTrace Logo

Open Label Extension Study With Gefitinib (IRESSA™) for Completing Trial Patients Who May Benefit From Further Treatment

NCT00683306 · Status: APPROVED_FOR_MARKETING · Type: EXPANDED_ACCESS

Last updated 2018-09-13

No results posted yet for this study

Summary

The purpose of this study is to provide gefitinib treatment to patients who, on completion or closure of other gefitinib clinical studies, were either receiving placebo treatment, or are continuing on the same dose and regimen of gefitinib established in their preceding study, for as long as the patients continue to derive benefit.

Conditions

  • Non Small Cell Lung Cancer (NSCLC)

Interventions

DRUG

ZD1839 (Iressa)

Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.

Sponsors & Collaborators

Principal Investigators

  • Yuri Rukazenkov · AstraZeneca

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Argentina
  • Australia
  • Austria
  • Brazil
  • Bulgaria
  • Estonia
  • Hungary
  • India
  • Latvia
  • Malaysia
  • Mexico
  • Philippines
  • Romania
  • Russia
  • Singapore
  • South Africa
  • Taiwan
  • Thailand
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683306 on ClinicalTrials.gov